New research reveals that people who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt conventional diet and exercise regimens.
Research printed in a prominent health publication demonstrates that while obese individuals frequently drop about a fifth of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People using such medications should be aware of the potential of quick rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment mass within about one and a half years.
Weighing Treatments
The study, which reviewed 37 of trials involving thousands of participants, contrasted the outcomes of the injectable medications with conventional dieting.
The team point out that individuals who shed pounds through lifestyle changes alone generally see a more gradual creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Fast Regain
Experts propose the mode of action of the drugs explains the heightened rebound.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to hunger is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
The NHS recommend the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Professionals say that, considering the significant potential of relapse, the treatment is often life-long.
This perspective is supported by drug manufacturers, who note that the results "underscore the chronic character of obesity," comparing it to managing diseases like hypertension.
User Accounts
Users who have come off the medication explain a sudden return of cravings.
"I experienced a trigger flipping and you become starving," recalled one woman.
The struggle is compounded if patients have not adopted lasting dietary or behavioural changes during therapy.
Widespread Adoption
Survey data show that millions of adults in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and lasting health benefits hinges on combined lifestyle changes.
